{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,12,31]],"date-time":"2025-12-31T02:48:52Z","timestamp":1767149332078,"version":"build-2238731810"},"reference-count":47,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2018,10,1]],"date-time":"2018-10-01T00:00:00Z","timestamp":1538352000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":["clinicalkey.es","elsevier.es","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Revista Iberoamericana de Micolog\u00eda"],"published-print":{"date-parts":[[2018,10]]},"DOI":"10.1016\/j.riam.2018.07.003","type":"journal-article","created":{"date-parts":[[2018,11,16]],"date-time":"2018-11-16T18:41:28Z","timestamp":1542393688000},"page":"192-197","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":5,"title":["Opciones terap\u00e9uticas actuales en las micosis invasoras y papel terap\u00e9utico potencial del isavuconazol"],"prefix":"10.1016","volume":"35","author":[{"given":"Carolina","family":"Garcia-Vidal","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.riam.2018.07.003_bib0235","doi-asserted-by":"crossref","first-page":"3380","DOI":"10.1128\/AAC.00383-13","article-title":"Population-based survey of filamentous fungi and antifungal resistance in Spain (FILPOP Study)","volume":"57","author":"Alastruey-Izquierdo","year":"2013","journal-title":"Antimicrob Agents Chemother."},{"key":"10.1016\/j.riam.2018.07.003_bib0240","doi-asserted-by":"crossref","first-page":"7735","DOI":"10.1128\/AAC.01919-15","article-title":"In vitro activity of isavuconazole and comparators against clinical isolates of the Mucorales order","volume":"59","author":"Arendrup","year":"2015","journal-title":"Antimicrob Agents Chemother."},{"key":"10.1016\/j.riam.2018.07.003_bib0245","doi-asserted-by":"crossref","DOI":"10.1128\/AAC.00485-17","article-title":"Comparison of EUCAST and CLSI reference microdilution MICs of eight antifungal compounds for Candida auris and associated tentative epidemiological cutoff values","volume":"61","author":"Arendrup","year":"2017","journal-title":"Antimicrob Agents Chemother."},{"key":"10.1016\/j.riam.2018.07.003_bib0250","unstructured":"Astellas P. Astellas provides update on phase 3 study evaluating isavuconazole in patients with candidemia and other invasive candidal infections [news release], 2016 [consultado 13 Mar 2016]. Disponible en: http:\/\/newsroom.astellas.us\/2015-07-30-Astellas-Provides-Update-on-Phase-3-StudyEvaluating-Isavuconazole-in-Patients-with-Candidemia-and-OtherInvasive-Candida-Infections"},{"key":"10.1016\/j.riam.2018.07.003_bib0255","doi-asserted-by":"crossref","first-page":"1855","DOI":"10.3201\/eid1710.110087","article-title":"Invasive non-Aspergillus mold infections in transplant recipients, United States, 2001-2006","volume":"17","author":"Park","year":"2011","journal-title":"Emerg Infect Dis."},{"key":"10.1016\/j.riam.2018.07.003_bib0260","doi-asserted-by":"crossref","first-page":"2116","DOI":"10.1093\/jac\/dkq279","article-title":"Azole antifungal resistance in Aspergillus fumigatus: 2008 and 2009","volume":"65","author":"Bueid","year":"2010","journal-title":"J Antimicrob Chemother."},{"key":"10.1016\/j.riam.2018.07.003_bib0265","unstructured":"Cardozo C, Calabuig E, Gioia F, Escol\u00e1-Verg\u00e9 L, Fern\u00e1ndez-Ruiz M, L\u00f3pez-Cort\u00e9s LE, et al. Epidemiological changes in candidaemia in Spain: data from two prospective multicenter studies. ECCMID; Madrid: 2018."},{"key":"10.1016\/j.riam.2018.07.003_bib0270","doi-asserted-by":"crossref","first-page":"140","DOI":"10.1093\/cid\/cix687","article-title":"Call for action: Invasive fungal infections associated with ibrutinib and other small molecule kinase inhibitors targeting immune signaling pathways","volume":"66","author":"Chamilos","year":"2018","journal-title":"Clin Infect Dis."},{"key":"10.1016\/j.riam.2018.07.003_bib0275","doi-asserted-by":"crossref","first-page":"684.e1-9","DOI":"10.1016\/j.cmi.2015.02.029","article-title":"A simple prediction score for estimating the risk of candidaemia caused by fluconazole non-susceptible strains","volume":"21","author":"Cuervo","year":"2015","journal-title":"Clin Microbiol Infect."},{"key":"10.1016\/j.riam.2018.07.003_bib0280","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1183\/13993003.00583-2015","article-title":"Chronic pulmonary aspergillosis: Rationale and clinical guidelines for diagnosis and management","volume":"47","author":"Denning","year":"2015","journal-title":"Eur Respir J."},{"key":"10.1016\/j.riam.2018.07.003_bib0285","doi-asserted-by":"crossref","first-page":"3823","DOI":"10.1128\/AAC.00636-13","article-title":"Multicenter study of isavuconazole MIC distributions and epidemiological cutoff values for Aspergillus spp. for the CLSI M38-A2 broth microdilution method","volume":"57","author":"Espinel-Ingroff","year":"2013","journal-title":"Antimicrob Agents Chemother."},{"key":"10.1016\/j.riam.2018.07.003_bib0290","article-title":"Clinical practice guideline for the management of invasive diseases caused by Aspergillus: 2017 Update by the GEMICOMED-SEIMC\/REIPI","author":"Garcia-Vidal","year":"2018","journal-title":"Enf Infec Microbiol."},{"key":"10.1016\/j.riam.2018.07.003_bib0295","doi-asserted-by":"crossref","first-page":"e0120370","DOI":"10.1371\/journal.pone.0120370","article-title":"Causes of death in a contemporary cohort of patients with invasive aspergillosis","volume":"10","author":"Garcia-Vidal","year":"2015","journal-title":"PLoS ONE."},{"key":"10.1016\/j.riam.2018.07.003_bib0300","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1016\/j.riam.2014.09.001","article-title":"Inmunopatolog\u00eda de las micosis invasivas por hongos filamentosos","volume":"31","author":"Garcia-Vidal","year":"2014","journal-title":"Rev Iberoam Micol."},{"key":"10.1016\/j.riam.2018.07.003_bib0305","doi-asserted-by":"crossref","first-page":"270","DOI":"10.1097\/QCO.0b013e32835fb920","article-title":"Pathogenesis of invasive fungal infections","volume":"26","author":"Garcia-Vidal","year":"2013","journal-title":"Curr Opin Infect Dis."},{"key":"10.1016\/j.riam.2018.07.003_bib0310","doi-asserted-by":"crossref","first-page":"2091","DOI":"10.1056\/NEJMoa1004383","article-title":"Reduced mortality after allogeneic hematopoietic-cell transplantation","volume":"363","author":"Gooley","year":"2010","journal-title":"N Engl J Med."},{"key":"10.1016\/j.riam.2018.07.003_bib0315","doi-asserted-by":"crossref","DOI":"10.1111\/tid.12751","article-title":"Drug-drug interactions between triazole antifungal agents used to treat invasive aspergillosis and immunosuppressants metabolized by cytochrome P450 3A4","volume":"19","author":"Groll","year":"2017","journal-title":"Transpl Infect Dis."},{"key":"10.1016\/j.riam.2018.07.003_bib0320","doi-asserted-by":"crossref","first-page":"728","DOI":"10.3111\/13696998.2016.1164175","article-title":"Hospital resource use of patients receiving isavuconazole vs voriconazole for invasive mold infections in the phase III SECURE trial","volume":"19","author":"Horn","year":"2016","journal-title":"J Med Econ."},{"key":"10.1016\/j.riam.2018.07.003_bib0325","doi-asserted-by":"crossref","first-page":"R253","DOI":"10.1186\/cc10514","article-title":"Anidulafungin compared with fluconazole therapy in critically ill patients","volume":"15","author":"Kett","year":"2011","journal-title":"Crit Care."},{"key":"10.1016\/j.riam.2018.07.003_bib0330","doi-asserted-by":"crossref","unstructured":"Kullberg BJ, Viscoli C, Pappas PG, Vazquez J, Ostrosky-Zeichner L, Rotstein C, et al. Isavuconazole versus Caspofungin in the Treatment of Candidemia and Other Invasive Candida Infections: The ACTIVE Trial. Clin Infect Dis. 2018 Oct 5. doi:10.1093\/cid\/ciy827.","DOI":"10.1093\/cid\/ciy827"},{"key":"10.1016\/j.riam.2018.07.003_bib0335","doi-asserted-by":"crossref","first-page":"S35","DOI":"10.1093\/cid\/cir880","article-title":"A global analysis of mucormycosis in France: The RetroZygo Study (2005-2007)","volume":"54 Suppl 1","author":"Lanternier","year":"2012","journal-title":"Clin Infect Dis."},{"key":"10.1016\/j.riam.2018.07.003_bib0340","doi-asserted-by":"crossref","first-page":"134","DOI":"10.1093\/cid\/ciw691","article-title":"Simultaneous emergence of multidrug-resistant Candida auris on 3 continents confirmed by whole-genome sequencing and epidemiological analyses","volume":"64","author":"Lockhart","year":"2017","journal-title":"Clin Infect Dis."},{"key":"10.1016\/j.riam.2018.07.003_bib0345","doi-asserted-by":"crossref","first-page":"733.e1-8","DOI":"10.1016\/j.cmi.2016.05.008","article-title":"Empirical and targeted therapy of candidemia with fluconazole versus echinocandins: A propensity score-derived analysis of a population-based, multicentre prospective cohort","volume":"22","author":"L\u00f3pez-Cort\u00e9s","year":"2016","journal-title":"Clin Microbiol Infect."},{"key":"10.1016\/j.riam.2018.07.003_bib0350","doi-asserted-by":"crossref","first-page":"760","DOI":"10.1016\/S0140-6736(15)01159-9","article-title":"Isavuconazole versus voriconazole for primary treatment of invasive mould disease caused by Aspergillus and other filamentous fungi (SECURE): A phase 3, randomised-controlled, non-inferiority trial","volume":"387","author":"Maertens","year":"2016","journal-title":"Lancet."},{"key":"10.1016\/j.riam.2018.07.003_bib0355","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1086\/315193","article-title":"Candidemia in allogeneic blood and marrow transplant recipients: Evolution of risk factors after the adoption of prophylactic fluconazole","volume":"181","author":"Marr","year":"2000","journal-title":"J Infect Dis."},{"key":"10.1016\/j.riam.2018.07.003_bib0360","doi-asserted-by":"crossref","first-page":"828","DOI":"10.1016\/S1473-3099(16)00071-2","article-title":"Isavuconazole treatment for mucormycosis: A single-arm open-label trial and case-control analysis","volume":"16","author":"Marty","year":"2016","journal-title":"Lancet Infect Dis."},{"key":"10.1016\/j.riam.2018.07.003_bib0365","doi-asserted-by":"crossref","first-page":"E251","DOI":"10.1016\/S1473-3099(16)30138-4","article-title":"In-host adaptation and acquired triazole resistance in Aspergillus fumigatus: A dilemma for clinical management","volume":"16","author":"Verweij","year":"2016","journal-title":"Lancet Infect Dis."},{"key":"10.1016\/j.riam.2018.07.003_bib0370","doi-asserted-by":"crossref","first-page":"913","DOI":"10.1093\/cid\/cir969","article-title":"Administration of voriconazole in patients with renal dysfunction","volume":"54","author":"Neofytos","year":"2012","journal-title":"Clin Infect Dis."},{"key":"10.1016\/j.riam.2018.07.003_bib0375","doi-asserted-by":"crossref","first-page":"521","DOI":"10.1086\/432060","article-title":"Emerging fungal diseases","volume":"41","author":"Nucci","year":"2005","journal-title":"Clin Infect Dis."},{"key":"10.1016\/j.riam.2018.07.003_bib0380","doi-asserted-by":"crossref","first-page":"1529","DOI":"10.1093\/cid\/ciw585","article-title":"Real-life use of isavuconazole in patients intolerant to other azoles","volume":"63","author":"Ordaya","year":"2016","journal-title":"Clin Infect Dis."},{"key":"10.1016\/j.riam.2018.07.003_bib0385","doi-asserted-by":"crossref","first-page":"562","DOI":"10.1093\/jac\/dkp495","article-title":"Candida spp. bloodstream infection: Influence of antifungal treatment on outcome","volume":"65","author":"Ortega","year":"2010","journal-title":"J Antimicrob Chemother."},{"key":"10.1016\/j.riam.2018.07.003_bib0390","doi-asserted-by":"crossref","first-page":"1101","DOI":"10.1086\/651262","article-title":"Invasive fungal infections among organ transplant recipients: results of the Transplant-Associated Infection Surveillance Network (TRANSNET)","volume":"50","author":"Pappas","year":"2010","journal-title":"Clin Infect Dis."},{"key":"10.1016\/j.riam.2018.07.003_bib0395","doi-asserted-by":"crossref","first-page":"e1","DOI":"10.1093\/cid\/civ1194","article-title":"Clinical practice guideline for the management of candidiasis: 2016 update by the Infectious Diseases Society of America","volume":"62","author":"Pappas","year":"2016","journal-title":"Clin Infect Dis."},{"key":"10.1016\/j.riam.2018.07.003_bib0400","doi-asserted-by":"crossref","first-page":"1080","DOI":"10.1093\/cid\/cis599","article-title":"The effect of therapeutic drug monitoring on safety and efficacy of voriconazole in invasive fungal infections: A randomized controlled trial","volume":"55","author":"Park","year":"2012","journal-title":"Clin Infect Dis."},{"key":"10.1016\/j.riam.2018.07.003_bib0405","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1086\/524669","article-title":"Voriconazole therapeutic drug monitoring in patients with invasive mycoses improves efficacy and safety outcomes","volume":"46","author":"Pascual","year":"2008","journal-title":"Clin Infect Dis."},{"key":"10.1016\/j.riam.2018.07.003_bib0410","first-page":"1","article-title":"Unusual forms of subacute invasive pulmonary aspergillosis in patients with solid tumors","author":"Peghin","year":"2014","journal-title":"J Infect."},{"key":"10.1016\/j.riam.2018.07.003_bib0415","doi-asserted-by":"crossref","first-page":"396","DOI":"10.1128\/JCM.01398-10","article-title":"Geographic variations in species distribution and echinocandin and azole antifungal resistance rates among Candida bloodstream infection isolates: Report from the SENTRY Antimicrobial Surveillance Program (2008 to 2009)","volume":"49","author":"Pfaller","year":"2011","journal-title":"J Clin Microbiol."},{"key":"10.1016\/j.riam.2018.07.003_bib0420","doi-asserted-by":"crossref","first-page":"303","DOI":"10.1016\/j.diagmicrobio.2015.04.008","volume":"82","author":"Pfaller","year":"2015","journal-title":"Diagn Microbiol Infect Dis."},{"key":"10.1016\/j.riam.2018.07.003_bib0425","author":"Richardson","year":"2017","journal-title":"Isavuconazole levels in non-compromised patients treated for chronic pulmonary aspergillosis 27th ECCMID"},{"key":"10.1016\/j.riam.2018.07.003_bib0430","doi-asserted-by":"crossref","first-page":"498","DOI":"10.1111\/myc.12781","article-title":"An outbreak due to Candida auris with prolonged colonisation and candidaemia in a tertiary care European hospital","volume":"61","author":"Ruiz-Gait\u00e1n","year":"2018","journal-title":"Mycoses."},{"key":"10.1016\/j.riam.2018.07.003_bib0435","doi-asserted-by":"crossref","first-page":"1037","DOI":"10.1002\/phar.1652","article-title":"Isavuconazole: Pharmacology, pharmacodynamics, and current clinical experience with a new triazole antifungal agent","volume":"35","author":"Rybak","year":"2015","journal-title":"Pharmacotherapy."},{"key":"10.1016\/j.riam.2018.07.003_bib0440","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1128\/AAC.02157-15","article-title":"Activity of isavuconazole and other azoles against Candida clinical isolates and yeast model systems with known azole resistance mechanisms","volume":"60","author":"Sanglard","year":"2016","journal-title":"Antimicrob Agents Chemother."},{"key":"10.1016\/j.riam.2018.07.003_bib0445","doi-asserted-by":"crossref","first-page":"356","DOI":"10.1093\/cid\/ciw305","article-title":"Isavuconazole treatment of cryptococcosis and dimorphic mycoses","volume":"63","author":"Thompson","year":"2016","journal-title":"Clin Infect Dis."},{"key":"10.1016\/j.riam.2018.07.003_bib0450","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1016\/S0025-6196(11)60839-2","article-title":"Fungal infections complicating tumor necrosis factor alpha blockade therapy","volume":"83","author":"Tsiodras","year":"2008","journal-title":"Mayo Clin Proc."},{"issue":"Suppl 1","key":"10.1016\/j.riam.2018.07.003_bib0455","doi-asserted-by":"crossref","first-page":"e1","DOI":"10.1016\/j.cmi.2018.01.002","article-title":"Diagnosis and management of Aspergillus diseases: Executive summary of the 2017 ESCMID-ECMM-ERS guideline","volume":"24","author":"Ullmann","year":"2018","journal-title":"Clin Microbiol Infect."},{"key":"10.1016\/j.riam.2018.07.003_bib0460","doi-asserted-by":"crossref","first-page":"531","DOI":"10.1086\/510592","article-title":"Invasive aspergillosis following hematopoietic cell transplantation: Outcomes and prognostic factors associated with mortality","volume":"44","author":"Upton","year":"2007","journal-title":"Clin Infect Dis."},{"key":"10.1016\/j.riam.2018.07.003_bib0465","doi-asserted-by":"crossref","first-page":"1671","DOI":"10.1128\/AAC.04586-14","article-title":"A phase 2, randomized, double-blind, multicenter trial to evaluate the safety and efficacy of three dosing regimens of isavuconazole compared with fluconazole in patients with uncomplicated esophageal candidiasis","volume":"59","author":"Viljoen","year":"2015","journal-title":"Antimicrob Agents Chemother."}],"updated-by":[{"DOI":"10.1016\/j.riam.2019.10.001","type":"erratum","label":"Erratum","source":"publisher","updated":{"date-parts":[[2019,7,1]],"date-time":"2019-07-01T00:00:00Z","timestamp":1561939200000}}],"container-title":["Revista Iberoamericana de Micolog\u00eda"],"original-title":[],"language":"es","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1130140618300603?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1130140618300603?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2019,11,5]],"date-time":"2019-11-05T20:44:18Z","timestamp":1572986658000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1130140618300603"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,10]]},"references-count":47,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2018,10]]}},"alternative-id":["S1130140618300603"],"URL":"https:\/\/doi.org\/10.1016\/j.riam.2018.07.003","relation":{},"ISSN":["1130-1406"],"issn-type":[{"value":"1130-1406","type":"print"}],"subject":[],"published":{"date-parts":[[2018,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Opciones terap\u00e9uticas actuales en las micosis invasoras y papel terap\u00e9utico potencial del isavuconazol","name":"articletitle","label":"Article Title"},{"value":"Revista Iberoamericana de Micolog\u00eda","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.riam.2018.07.003","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2018 Asociaci\u00f3n Espa\u00f1ola de Micolog\u00eda. Published by Elsevier Espa\u00f1a, S.L.U. All rights reserved.","name":"copyright","label":"Copyright"}]}}